Progressive, unstable or uncontrolled clinical conditions.
Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
Clinical conditions.
Systemic administration of corticosteroids (PO/IV/IM) within 90 days prior to informed consent.
Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
Received immunoglobulins or any blood products within 180 days prior to informed consent.
Received an investigational or non-registered medicinal product within 30 days prior to informed consent.
Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
Any history of meningococcal vaccination or meningococcal and gonorrhoea diseases.
Enrolment in any activity requiring a blood donation greater than 50 mL during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period.
Administration of long-acting immune-modifying drugs at any time during the study period
Subjects with blood disorders.
Subjects with a history of difficulty in providing blood samples
Any antibiotic intake 7 days prior to blood collection.
Subjects who donated >450 mL of blood within 60 days prior to any blood collection visits.
Subjects who lost >200 mL during a single apheresis or who lost red blood cells on more than one occasion during apheresis within the previous 60 days.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
Ongoing anaemia as indicated by haemoglobin values below the lower limit of the laboratory-specified reference range. If the finger prick method demonstrates an anaemia, no further protocol procedures will be performed, and the subject will be referred for appropriate medical management. The subject may participate in this study following therapy and evidence that the anaemia has been resolved.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
Pregnant or lactating female.
Female planning to become pregnant or planning to discontinue contraceptive precautions.
Any confirmed or suspected immunosuppressive or immunodeficiency condition based on medical history and physical examination
Family history of congenital or hereditary immunodeficiency.
Serious chronic illness.
History of chronic alcohol consumption and/or drug abuse.

NCT03493919_exc_T1
Qualifier
uncontrolled
NCT03493919_exc_T2
Qualifier
unstable
NCT03493919_exc_T3
Qualifier
Progressive
NCT03493919_exc_T4
Condition
clinical conditions
NCT03493919_exc_T5
Scope
Progressive, unstable or uncontrolled
NCT03493919_exc_T6
Condition
Hypersensitivity
NCT03493919_exc_T7
Condition
allergy
NCT03493919_exc_T8
Drug
component of vaccines
NCT03493919_exc_T9
Drug
medicinal products
NCT03493919_exc_T10
Device
medical equipment
NCT03493919_exc_T11
Qualifier
whose use is foreseen in this study
NCT03493919_exc_T12
Scope
component of vaccines, medicinal products or medical equipment
NCT03493919_exc_T13
Scope
Hypersensitivity, including allergy
NCT03493919_exc_T14
Condition
contraindication
NCT03493919_exc_T15
Procedure
intramuscular vaccination
NCT03493919_exc_T16
Procedure
blood draws
NCT03493919_exc_T17
Scope
intramuscular vaccination and blood draws
NCT03493919_exc_T19
Qualifier
Systemic administration
NCT03493919_exc_T20
Drug
corticosteroids
NCT03493919_exc_T21
Qualifier
PO
NCT03493919_exc_T22
Qualifier
IV
NCT03493919_exc_T23
Qualifier
IM
NCT03493919_exc_T24
Scope
PO/IV/IM
NCT03493919_exc_T25
Temporal
within 90 days prior to informed consent
NCT03493919_exc_T26
Reference_point
informed consent
NCT03493919_exc_T27
Drug
immunomodulating agents
NCT03493919_exc_T28
Drug
eoplastic and s or r
NCT03493919_exc_T29
Procedure
radiotherapy
NCT03493919_exc_T30
Temporal
within 90 days prior to informed consent
NCT03493919_exc_T31
Reference_point
informed consent
NCT03493919_exc_T32
Scope
antineoplastic and immunomodulating agents or radiotherapy
NCT03493919_exc_T33
Drug
immunoglobulins
NCT03493919_exc_T34
Drug
blood products
NCT03493919_exc_T35
Temporal
within 180 days prior to informed consent
NCT03493919_exc_T36
Reference_point
informed consent
NCT03493919_exc_T37
Scope
immunoglobulins or any blood products
NCT03493919_exc_T38
Qualifier
investigational
NCT03493919_exc_T39
Qualifier
non-registered
NCT03493919_exc_T40
Drug
medicinal product
NCT03493919_exc_T41
Temporal
within 30 days prior to informed consent
NCT03493919_exc_T42
Reference_point
informed consent
NCT03493919_exc_T43
Scope
investigational or non-registered
NCT03493919_exc_T45
Drug
meningococcal vaccination
NCT03493919_exc_T46
Observation
history
NCT03493919_exc_T47
Condition
ccal and gono 
Enrolm
NCT03493919_exc_T48
Condition
gonorrhoea diseases
NCT03493919_exc_T49
Scope
meningococcal vaccination or meningococcal and gonorrhoea diseases
NCT03493919_exc_T50
Procedure
blood donation
NCT03493919_exc_T52
Multiplier
greater than 50 mL
NCT03493919_exc_T53
Temporal
during the period starting 30 days before the first study visit
NCT03493919_exc_T54
Reference_point
30 days before the first study visit
NCT03493919_exc_T55
Temporal
for the duration of the study period
NCT03493919_exc_T56
Reference_point
the study period
NCT03493919_exc_T57
Scope
during the period starting 30 days before the first study visit (Day -83, Day -60 or Day -30) or for the duration of the study period
NCT03493919_exc_T58
Drug
immune-modifying drugs
NCT03493919_exc_T59
Temporal
at any time during the study period
NCT03493919_exc_T60
Reference_point
the study period
NCT03493919_exc_T61
Qualifier
long-acting
NCT03493919_exc_T62
Condition
blood disorders
NCT03493919_exc_T63
Observation
history
NCT03493919_exc_T64
Observation
difficulty in providing blood samples
NCT03493919_exc_T65
Drug
antibiotic
NCT03493919_exc_T66
Temporal
7 days prior to blood collection
NCT03493919_exc_T67
Reference_point
blood collection
NCT03493919_exc_T68
Procedure
 of bl  day
NCT03493919_exc_T69
Value
>450 mL
NCT03493919_exc_T70
Temporal
within 60 days prior to any blood collection visits
NCT03493919_exc_T71
Reference_point
any blood collection visits
NCT03493919_exc_T72
Measurement
lost red blood cells
NCT03493919_exc_T73
Value
>200 mL
NCT03493919_exc_T74
Multiplier
single
NCT03493919_exc_T75
Procedure
apheresis
NCT03493919_exc_T76
Procedure
apheresis
NCT03493919_exc_T77
Multiplier
more than one occasion
NCT03493919_exc_T78
Temporal
within the previous 60 days
NCT03493919_exc_T79
Reference_point
the previous 60 days
NCT03493919_exc_T80
Temporal
Concurrently
NCT03493919_exc_T81
Observation
another clinical t any time dur
NCT03493919_exc_T82
Temporal
at any time during the study period
NCT03493919_exc_T83
Reference_point
the study period
NCT03493919_exc_T84
Drug
vaccine
NCT03493919_exc_T85
Drug
product
NCT03493919_exc_T86
Scope
vaccine/product
NCT03493919_exc_T87
Qualifier
investigational
NCT03493919_exc_T88
Qualifier
non-investigational
NCT03493919_exc_T89
Scope
investigational or a non-investigational
NCT03493919_exc_T90
Temporal
Ongoing
NCT03493919_exc_T91
Condition
anaemia
NCT03493919_exc_T92
Measurement
haemoglobin
NCT03493919_exc_T93
Value
below the lower limit of the laboratory-specified reference range
NCT03493919_exc_T94
Procedure
finger prick method
NCT03493919_exc_T95
Condition
anaemia
NCT03493919_exc_T97
Condition
reaction
NCT03493919_exc_T98
Condition
hypersensitivity
NCT03493919_exc_T99
Qualifier
likely to be exacerbated by any component of the vaccines
NCT03493919_exc_T100
Drug
component of the vaccines
NCT03493919_exc_T101
Scope
reaction or hypersensitivity
NCT03493919_exc_T102
Condition
Pregnant
NCT03493919_exc_T103
Observation
lactating
NCT03493919_exc_T104
Person
female
NCT03493919_exc_T105
Person
Female
NCT03493919_exc_T106
Observation
planning to become pregnant
NCT03493919_exc_T107
Mood
planning to discontinue
NCT03493919_exc_T108
Observation
contraceptive precautions
NCT03493919_exc_T109
Mood
planning to
NCT03493919_exc_T110
Observation
become pregnant
NCT03493919_exc_T111
Qualifier
confirmed
NCT03493919_exc_T112
Mood
suspected
NCT03493919_exc_T113
Condition
mmunodeficiency c ical hist
NCT03493919_exc_T114
Condition
immunodeficiency condition
NCT03493919_exc_T115
Observation
medical history
NCT03493919_exc_T116
Procedure
physical examination
NCT03493919_exc_T117
Scope
medical history and physical examination
NCT03493919_exc_T118
Scope
immunosuppressive or immunodeficiency condition
NCT03493919_exc_T119
Scope
confirmed or suspected
NCT03493919_exc_T120
Observation
Family history
NCT03493919_exc_T121
Condition
hereditary immunodeficiency
NCT03493919_exc_T122
Condition
y immunode us chronic illne
NCT03493919_exc_T123
Scope
congenital or hereditary immunodeficiency
NCT03493919_exc_T124
Qualifier
Serious
NCT03493919_exc_T125
Condition
chronic illness
NCT03493919_exc_T126
Condition
chronic alcohol consumption
NCT03493919_exc_T127
Condition
drug abuse
NCT03493919_exc_T128
Observation
History
NCT03493919_exc_T129
Scope
chronic alcohol consumption and/or drug abuse